Finance

Loss of $16.6M reported by cancer therapeutics firm; trial updates provided

Published in Cancer Weekly, August 19th, 2003

Antigenics, Inc., (AGEN) reported results for the quarter ended June 30, 2003, and provided an update on its clinical trials.

The company incurred a net loss of $16.6 million, or $0.42 per share, basic and diluted. This is compared with a net loss in the second quarter of 2002 of $14.1 million, or $0.43 per share, basic and diluted. Research and development costs were $12 million in the second quarter of 2003, compared with $10 million for the same period in 2002.

The increased losses reflect the further progress of the company's clinical product candidates including Oncophage (HSPPC-96), Antigenics' lead product candidate in phase III development,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-08-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry